Mineralys Therapeutics, Inc. (MLYS) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Radnor, PA, 美国. 現任CEO為 Jon Congleton.
MLYS 擁有 IPO日期為 2023-02-10, 51 名全職員工, 在 NASDAQ Global Select, 市值為 $1.81B.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
